[
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Top Trump lawyer calls on SCOTUS to reverse 'skinny' generic drug label decision",
    "summary": "```json\n{\n  \"summary\": \"President Trump's Solicitor General John Sauer has requested the Supreme Court to review a decision regarding 'skinny' generic drug labels. The case could impact generic drugma",
    "url": "https://endpoints.news/top-trump-lawyer-calls-on-scotus-to-reverse-skinny-generic-drug-label-decision/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Umoja delays first readout for in vivo CAR-T therapy",
    "summary": "```json\n{\n  \"summary\": \"Umoja Biopharma has announced a delay in the first clinical readout from its China-based trial for its in vivo CAR-T therapy. The company, which is among the most well-funded d",
    "url": "https://endpoints.news/umoja-delays-first-readout-for-in-vivo-car-t-therapy/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "AC Immune says early biomarker data are promising in Parkinson's, but clinical benefit remains unclear",
    "summary": "```json\n{\n  \"summary\": \"AC Immune reported interim Parkinson's disease data showing promising early biomarker results that suggest their immunological treatment may slow disease progression. However, ",
    "url": "https://endpoints.news/ac-immune-says-early-biomarker-data-are-promising-in-parkinsons-but-clinical-benefit-remains-unclear/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Health tech investors are getting creative with exits",
    "summary": "```json\n{\n  \"summary\": \"Health tech investors are exploring creative exit strategies as the market shows signs of recovery. Following market uncertainty earlier in the year, investors are seeking alte",
    "url": "https://endpoints.news/health-tech-investors-are-getting-creative-with-exits/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Rhythm reports Imcivree’s key weight loss data from Phase 2 Prader-Willi trial",
    "summary": "```json\n{\n  \"summary\": \"Rhythm Pharmaceuticals reported positive Phase 2 data for Imcivree, an MC4R agonist, in Prader-Willi syndrome patients. The drug demonstrated BMI reductions in six out of eight",
    "url": "https://endpoints.news/rhythm-reports-imcivrees-key-weight-loss-data-from-phase-2-prader-willi-trial/",
    "date": "2025-12-11",
    "companies_detected": [
      "Rhythm Pharmaceuticals"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Zealand inks deal with OTR Therapeutics as it spells out broader metabolic disease ambitions",
    "summary": "```json\n{\n  \"summary\": \"Zealand Pharma has entered into a partnership with Shanghai-based OTR Therapeutics, committing at least $20 million upfront to jointly discover and develop new targets for meta",
    "url": "https://endpoints.news/zealand-inks-deal-with-otr-therapeutics-as-it-spells-out-broader-metabolic-disease-ambitions/",
    "date": "2025-12-11",
    "companies_detected": [
      "Zealand Pharma"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Rezolute crashes as its only drug fails in Phase 3",
    "summary": "",
    "url": "https://endpoints.news/rezolute-crashes-as-its-only-drug-fails-in-phase-3/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Endpoints 100 survey 2025: Biotech CEOs are feeling more upbeat",
    "summary": "```json\n{\n  \"summary\": \"Endpoints News conducted a survey of biotech CEOs in 2025, revealing improved sentiment in the second half of the year. The industry had reached a low point in spring amid conc",
    "url": "https://endpoints.news/endpoints-100-survey-2025-biotech-ceos-are-feeling-more-upbeat/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Corbus’ obesity pill posts muted weight loss data; Disco adds another €16M in seed funding",
    "summary": "",
    "url": "https://endpoints.news/corbus-obesity-pill-posts-muted-weight-loss-data-disco-adds-another-e16m-in-seed-funding/",
    "date": "2025-12-11",
    "companies_detected": [
      "AstraZeneca",
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly's retatrutide, a triple-G agonist for obesity, demonstrated 23.7% average weight loss in patients with obesity and knee osteoarthritis at approximately 16 weeks. The ",
    "url": "https://endpoints.news/lillys-triple-agonist-posts-strongest-weight-loss-data-yet-but-unusual-skin-side-effect-reported/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Weight loss biotech Prolynx gets $70M, snags Amgen's obesity commercial leader as CEO",
    "summary": "```json\n{\n  \"summary\": \"Prolynx, a biotech company focused on long-acting anti-obesity treatments, has raised $70 million in funding. The company has appointed Amgen's former obesity commercial leader",
    "url": "https://endpoints.news/weight-loss-biotech-prolynx-gets-70m-snags-amgens-obesity-commercial-leader-as-ceo/",
    "date": "2025-12-11",
    "companies_detected": [
      "Amgen",
      "Prolynx"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "House backs Biosecure Act aimed at Chinese companies",
    "summary": "```json\n{\n  \"summary\": \"The U.S. House of Representatives approved a defense bill that includes a diluted version of the Biosecure Act, which aims to restrict federal contracts with certain Chinese bi",
    "url": "https://endpoints.news/house-backs-biosecure-act-aimed-at-chinese-companies/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Adare Pharma shutters Philadelphia site and lays off over 100 staffers",
    "summary": "```json\n{\n  \"summary\": \"Adare Pharma Solutions, a CDMO, is closing its Philadelphia facility and laying off 137 employees, approximately one year after moving its headquarters to Pennsylvania. The 128",
    "url": "https://endpoints.news/adare-pharma-shutters-philadelphia-site-and-lays-off-over-100-staffers/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Apple Tree files for bankruptcy as it seeks funds from Russian billionaire backer",
    "summary": "```json\n{\n  \"summary\": \"Apple Tree Partners, a venture capital firm, has filed for voluntary Chapter 11 bankruptcy protection in US bankruptcy court. The firm is seeking to restructure its operations ",
    "url": "https://endpoints.news/apple-tree-files-for-bankruptcy-as-it-seeks-funds-from-russian-billionaire-backer/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "USAntibiotics scores sped-up approval for amoxicillin",
    "summary": "```json\n{\n  \"summary\": \"USAntibiotics received FDA approval for its American-made extended-release amoxicillin approximately two months ahead of the standard timeline. This marks the first product app",
    "url": "https://endpoints.news/usantibiotics-scores-sped-up-approval-for-amoxicillin/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%",
    "summary": "```json\n{\n  \"summary\": \"Roche presented interim data at SABCS25 showing that their experimental breast cancer pill reduced the risk of invasive disease recurrence by 30% in patients treated directly a",
    "url": "https://endpoints.news/sabcs25-roches-breast-cancer-pill-cuts-post-surgery-disease-recurrence-risk-by-30/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "In a first, FDA approves a gene therapy from a nonprofit",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved Waskyra, a gene therapy for Wiskott-Aldrich syndrome, marking the first gene therapy approval from a nonprofit organization. This treatment provides a new ",
    "url": "https://endpoints.news/in-a-first-fda-approves-a-gene-therapy-from-a-nonprofit/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "J&J joins 'menin party' at ASH; GSK to work with Oxford BioTherapeutics",
    "summary": "",
    "url": "https://endpoints.news/j-gsk-to-work-with-oxford-biotherapeutics/",
    "date": "2025-12-10",
    "companies_detected": [
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "PsiThera gets $47.5M for oral I&I drugs after spinning out from Roivant",
    "summary": "```json\n{\n  \"summary\": \"PsiThera, a biotech spun out from Roivant, raised $47.5 million in Series A funding to develop oral drugs for inflammation and immunology. The company is developing an oral dru",
    "url": "https://endpoints.news/psithera-gets-47-5m-for-oral-ii-drugs-after-spinning-out-from-roivant/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Investors buy up stocks in biggest follow-on offering day in biotech history",
    "summary": "```json\n{\n  \"summary\": \"The biotech sector experienced a record-breaking day with $3.2 billion in follow-on stock offerings sold over a 24-hour period. Eight biotech companies priced their offerings f",
    "url": "https://endpoints.news/investors-buy-up-stocks-in-biggest-follow-on-offering-day-in-biotech-history/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "UK lowers new medicine rebate scheme to 14.5% for 2026",
    "summary": "```json\n{\n  \"summary\": \"The UK government announced a reduction in its drug rebate tax for new medicines to 14.5% for 2026, down from nearly 23%. This change follows details emerging from the UK-US tr",
    "url": "https://endpoints.news/uk-lowers-new-medicine-rebate-scheme-to-14-5-for-2026/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3",
    "summary": "```json\n{\n  \"summary\": \"D3 Bio, a Shanghai-based biotech company, has raised $108 million in Series B funding. The primary objective is to advance its lead drug candidate targeting KRAS G12C into glob",
    "url": "https://endpoints.news/d3-bio-raises-108m-to-take-next-gen-kras-g12c-drug-into-phase-3/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "BlossomHill gets another $84M for macrocyclic approach to EGFR",
    "summary": "```json\n{\n  \"summary\": \"BlossomHill Therapeutics, a San Diego-based biotech startup, has raised $84 million in additional funding to advance its macrocyclic approach targeting EGFR. The company has tw",
    "url": "https://endpoints.news/blossomhill-gets-another-84m-for-macrocyclic-approach-to-egfr/",
    "date": "2025-12-10",
    "companies_detected": [
      "AstraZeneca"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Formation Bio signs deal for TYK2 drug from China's Lynk",
    "summary": "```json\n{\n  \"summary\": \"Formation Bio has signed a deal with China's Lynk Pharmaceuticals to acquire a TYK2 inhibitor drug program. TYK2 has become a highly sought-after target in immunology since Tak",
    "url": "https://endpoints.news/formation-bio-signs-deal-for-tyk2-drug-from-chinas-lynk/",
    "date": "2025-12-10",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech is Hiring a Process Engineer",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech is recruiting for a Process Engineer position. This represents a corporate hiring initiative by the company. No specific therapeutic areas, drug molecules, or technol",
    "url": "https://www.delsitech.com/delsitech-is-hiring-a-process-engineer/",
    "date": "2025-12-11",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Appointment of Outi Heikkilä as Chief Operations Officer",
    "summary": "```json\n{\n  \"summary\": \"The announcement concerns the appointment of Outi Heikkilä to the position of Chief Operations Officer. This is a corporate leadership change, though no company name is specifi",
    "url": "https://www.delsitech.com/appointment-of-outi-heikkila-as-chief-operations-officer/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech Seeks an Experienced Quality Director",
    "summary": "",
    "url": "https://www.delsitech.com/delsitech-seeks-an-experienced-quality-director/",
    "date": "2025-12-11",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech announces a leadership change. Carl-Åke Carlsson, CEO of DelSiTech, leaves the company and the Board nominates Martti Hedman as Interim CEO.",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech announces a leadership transition with CEO Carl-Åke Carlsson departing the company. The Board has appointed Martti Hedman to serve as Interim CEO following Carlsson's",
    "url": "https://www.delsitech.com/delsitech-announces-a-leadership-change-carl-ake-carlsson-ceo-of-delsitech-leaves-the-company-and-the-board-nominates-martti-hedman-as-interim-ceo/",
    "date": "2025-12-11",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "summary": "```json\n{\n  \"summary\": \"Partnership Opportunities in Drug Delivery 2025 is a conference scheduled to take place in Boston on October 27-28. This event appears to focus on collaboration and business de",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Drug Delivery and Formulation Summit 2025 Boston, September 15-16",
    "summary": "```json\n{\n  \"summary\": \"The Drug Delivery and Formulation Summit 2025 is scheduled to take place in Boston on September 15-16. This appears to be an industry conference focused on drug delivery techno",
    "url": "https://www.delsitech.com/drug-delivery-and-formulation-summit-2025-boston-september-15-16/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress Europe 2025 Amsterdam, October 13-16",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress Europe 2025 will be held in Amsterdam from October 13-16. This is a conference event focused on vaccine development and related topics in the pharmac",
    "url": "https://www.delsitech.com/world-vaccine-congress-europe-2025-amsterdam-october-13-16/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "summary": "```json\n{\n  \"summary\": \"The BIO International Convention 2025 will be held in Boston from June 16-19. This is an annual biotechnology industry event that brings together companies, researchers, and in",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress 2025 Washington, April 21-24",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress 2025 will be held in Washington from April 21-24. This is a conference event focused on vaccine development and related topics in the biotechnology a",
    "url": "https://www.delsitech.com/world-vaccine-congress-2025-washington-april-21-24/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the January-September 2025 period. This is a routine corporate disclosure providing updates on the company's financia",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "CRS Annual Meeting & Exposition 2025 Philadelphia, July 14-18",
    "summary": "```json\n{\n  \"summary\": \"The Controlled Release Society (CRS) Annual Meeting & Exposition 2025 will be held in Philadelphia from July 14-18. This is a major industry conference focused on controlled re",
    "url": "https://www.delsitech.com/crs-annual-meeting-exposition-2025-philadelphia-july-14-18/",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the January-September 2025 period. This is a routine corporate disclosure providing updates on the company's financia",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the first half of 2025 (January-June period). This is a routine corporate disclosure providing updates on the company",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "```json\n{\n  \"summary\": \"Unable to analyze the content as the provided text only contains 'Download attachment' without any actual biotech/pharma news content. No structured information can be extracte",
    "url": "https://storage.mfn.se/5d2c8421-0163-4592-8c9e-43752659a104/nanexa-interim-report-january-june-2025.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/marketing/amgen-obesity-marketing-leader-chris-boulton-takes-reins-metabolic-biotech-prolynx\" hreflang=\"en\">Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx</a>",
    "summary": "```json\n{\n  \"summary\": \"Chris Boulton, a veteran with three decades of sales and marketing experience at major pharmaceutical companies, has been appointed to lead Prolynx, a biotech company focused o",
    "url": "https://www.fiercebiotech.com/marketing/amgen-obesity-marketing-leader-chris-boulton-takes-reins-metabolic-biotech-prolynx",
    "date": "2025-12-11",
    "companies_detected": [
      "Amgen",
      "Prolynx"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/heartbeam-swells-turning-fda-rejection-ecg-clearance\" hreflang=\"en\">HeartBeam swells on turning FDA rejection into ECG clearance</a>",
    "summary": "```json\n{\n  \"summary\": \"HeartBeam received FDA clearance for its credit card-sized ECG system after initially facing rejection. The company plans to launch the product commercially in the new year. Th",
    "url": "https://www.fiercebiotech.com/medtech/heartbeam-swells-turning-fda-rejection-ecg-clearance",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025\" hreflang=\"en\">Fierce Biotech Layoff Tracker 2025: Geron lays off one-third of staff; Pfizer reduces Swiss staff</a>",
    "summary": "```json\n{\n  \"summary\": \"Fierce Biotech is tracking biotech and pharma layoffs in 2025. Geron has laid off one-third of its staff, while Pfizer is reducing its workforce in Switzerland. The publication",
    "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Read the presentation",
    "summary": "```json\n{\n  \"summary\": \"The text provided is insufficient for analysis as it only contains the phrase 'Read the presentation' without any substantive biotech/pharma news content. No companies, molecul",
    "url": "https://nanexa.com/wp-content/uploads/2025/11/PODD-Oct-2025.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/eli-lillys-obesity-triple-threat-smashes-efficacy-expectations-phase-3-proves-intolerable\" hreflang=\"en\">Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some</a>",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly's retatrutide, a triple agonist, demonstrated exceptional efficacy in phase 3 trials with 28.7% weight loss and 75.8% reduction in pain scores in patients with obesit",
    "url": "https://www.fiercebiotech.com/biotech/eli-lillys-obesity-triple-threat-smashes-efficacy-expectations-phase-3-proves-intolerable",
    "date": "2025-12-11",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/rezolutes-stock-plunges-87-after-hypoglycemia-drug-flunks-pivotal-phase-3-test\" hreflang=\"en\">Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test</a>",
    "summary": "```json\n{\n  \"summary\": \"Rezolute's stock dropped 87% following the failure of its rare disease drug candidate in a pivotal Phase 3 clinical trial. The drug was being developed for hypoglycemia and was",
    "url": "https://www.fiercebiotech.com/biotech/rezolutes-stock-plunges-87-after-hypoglycemia-drug-flunks-pivotal-phase-3-test",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/fda-approves-its-1st-non-drug-home-treatment-depression-flow-neurosciences-brain-headset\" hreflang=\"en\">FDA approves 1st nondrug, at-home treatment for depression</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved the first non-drug, at-home treatment for depression from Flow Neuroscience. The wearable brain headset is approved for use as a standalone treatment or in",
    "url": "https://www.fiercebiotech.com/medtech/fda-approves-its-1st-non-drug-home-treatment-depression-flow-neurosciences-brain-headset",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/fda-clears-lumos-labs-prescription-digital-therapy-treat-adhd-adults\" hreflang=\"en\">FDA clears Lumosity brain training games as a prescription app for adult ADHD</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/fda-clears-lumos-labs-prescription-digital-therapy-treat-adhd-adults",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/zealand-pens-25b-cardiometabolic-collab-fresh-faced-chinese-biotech\" hreflang=\"en\">Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech</a>",
    "summary": "```json\n{\n  \"summary\": \"Zealand Pharma has entered into a collaboration agreement with Chinese biotech OTR focused on oral cardiometabolic therapies. The deal includes up to $30 million in upfront pay",
    "url": "https://www.fiercebiotech.com/biotech/zealand-pens-25b-cardiometabolic-collab-fresh-faced-chinese-biotech",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/moderna-taps-nanexa-improve-delivery-injectable-therapies-back-loaded-500m-pact\" hreflang=\"en\">Moderna taps Nanexa to improve delivery of injectable therapies in back-loaded $500M pact</a>",
    "summary": "```json\n{\n  \"summary\": \"Moderna has entered into a partnership with Swedish company Nanexa to improve the delivery of up to four injectable therapies. The deal is structured with back-loaded payments ",
    "url": "https://www.fiercebiotech.com/biotech/moderna-taps-nanexa-improve-delivery-injectable-therapies-back-loaded-500m-pact",
    "date": "2025-12-11",
    "companies_detected": [
      "Nanexa"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/sanofi-gsk-ink-preclinical-pacts-quest-new-autoimmune-and-cancer-antibodies\" hreflang=\"en\">Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies</a>",
    "summary": "```json\n{\n  \"summary\": \"Sanofi and GSK have announced separate preclinical research partnerships. Sanofi is investing in a U.S. biotech company focused on autoimmune disease research, while GSK has pa",
    "url": "https://www.fiercebiotech.com/biotech/sanofi-gsk-ink-preclinical-pacts-quest-new-autoimmune-and-cancer-antibodies",
    "date": "2025-12-11",
    "companies_detected": [
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25\" hreflang=\"en\">Fierce Biotech Fundraising Tracker '25: Prolynx powers up with $70M series A; D3 Bio raises $108M</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
    "date": "2025-12-11",
    "companies_detected": [
      "Prolynx"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/gri-touts-ipf-safety-edge-lung-function-gains-amid-cash-crunch\" hreflang=\"en\">GRI touts IPF safety edge, lung function gains amid cash crunch</a>",
    "summary": "```json\n{\n  \"summary\": \"GRI Bio has released phase 2a clinical trial data for its idiopathic pulmonary fibrosis (IPF) therapy, highlighting safety advantages and improvements in lung function. The com",
    "url": "https://www.fiercebiotech.com/biotech/gri-touts-ipf-safety-edge-lung-function-gains-amid-cash-crunch",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/roche-links-oral-serd-30-breast-cancer-risk-reduction-phase-3-adjuvant-trial\" hreflang=\"en\">Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial</a>",
    "summary": "```json\n{\n  \"summary\": \"Roche announced positive phase 3 results for giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrating a 30% reduction in the risk of invasive disease re",
    "url": "https://www.fiercebiotech.com/biotech/roche-links-oral-serd-30-breast-cancer-risk-reduction-phase-3-adjuvant-trial",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/apple-tree-partners-files-chapter-11-bankruptcy-keep-cash-flowing-portfolio-biotechs\" hreflang=\"en\">Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/apple-tree-partners-files-chapter-11-bankruptcy-keep-cash-flowing-portfolio-biotechs",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/francis-medical-gets-fda-green-light-water-vapor-ablation-therapy-treat-prostate-cancer\" hreflang=\"en\">Francis Medical gets FDA green light for water vapor ablation to treat prostate cancer</a>",
    "summary": "```json\n{\n  \"summary\": \"Francis Medical received FDA 510(k) clearance for its water vapor ablation therapy to treat cancers of the prostate, kidneys, and bladder. This regulatory approval allows the c",
    "url": "https://www.fiercebiotech.com/medtech/francis-medical-gets-fda-green-light-water-vapor-ablation-therapy-treat-prostate-cancer",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/teleflex-inks-2b-divestment-deals-oem-urology-and-acute-care-units\" hreflang=\"en\">Teleflex inks $2B in divestment deals for OEM, urology and acute care units</a>",
    "summary": "```json\n{\n  \"summary\": \"Teleflex is divesting three business units in deals totaling approximately $2 billion. Private equity firms Montagu and Kohlberg are acquiring the OEM division for $1.5 billion",
    "url": "https://www.fiercebiotech.com/medtech/teleflex-inks-2b-divestment-deals-oem-urology-and-acute-care-units",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chinese-biotech-helmed-az-veteran-reels-108-series-b-kras-inhibitor-phase-3-plans\" hreflang=\"en\">Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans</a>",
    "summary": "```json\n{\n  \"summary\": \"A Chinese biotech company led by a former AstraZeneca executive has raised $108 million in Series B funding. The funds will be used to advance the company's lead KRAS inhibitor",
    "url": "https://www.fiercebiotech.com/biotech/chinese-biotech-helmed-az-veteran-reels-108-series-b-kras-inhibitor-phase-3-plans",
    "date": "2025-12-11",
    "companies_detected": [
      "AstraZeneca"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/strong-words-big-smiles-enduring-activism-and-cautious-optimism-american-society-hematology\" hreflang=\"en\">Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025</a>",
    "summary": "```json\n{\n  \"summary\": \"This article discusses the atmosphere and themes at the American Society of Hematology (ASH) 2025 conference held in Orlando. The piece focuses on the mood of 'enduring activis",
    "url": "https://www.fiercebiotech.com/biotech/strong-words-big-smiles-enduring-activism-and-cautious-optimism-american-society-hematology",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/bleekers-big-bang-formation-bio-unveils-new-subsidiary-605m-lynk-deal\" hreflang=\"en\">Bleecker's big bang: Formation Bio unveils new subsidiary with $605M Lynk deal </a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/bleekers-big-bang-formation-bio-unveils-new-subsidiary-605m-lynk-deal",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/medline-sets-terms-massive-537b-nasdaq-ipo\" hreflang=\"en\">Medline sets terms for massive $5.37B Nasdaq IPO</a>",
    "summary": "```json\n{\n  \"summary\": \"Medline, a medical device manufacturing and distribution company, has set terms for a massive $5.37 billion initial public offering on Nasdaq. The IPO could value the company a",
    "url": "https://www.fiercebiotech.com/medtech/medline-sets-terms-massive-537b-nasdaq-ipo",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/cro/fda-clears-1st-ai-drug-development-tool-reading-mash-images\" hreflang=\"en\">FDA qualifies 1st AI drug development tool for reading MASH images</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has qualified its first artificial intelligence tool designed to assist drug developers in evaluating fatty liver disease during clinical trials. This AI-based tool wil",
    "url": "https://www.fiercebiotech.com/cro/fda-clears-1st-ai-drug-development-tool-reading-mash-images",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug\" hreflang=\"en\">Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer has entered into a $1.9 billion biobucks deal with a Fosun unit, including $150 million upfront, to acquire a GLP-1 drug for obesity treatment. This partnership continue",
    "url": "https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-exicure-rebounds-phase-2-win-90-blood-cell-mobilization-myeloma\" hreflang=\"en\">ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Exicure reported positive phase 2 results for its investigational small molecule in multiple myeloma, achieving approximately 90% blood cell mobilization in patients. The succe",
    "url": "https://www.fiercebiotech.com/biotech/ash-exicure-rebounds-phase-2-win-90-blood-cell-mobilization-myeloma",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/geron-lay-13-workforce-quest-slash-operating-costs-maximize-rytelo-launch\" hreflang=\"en\">Geron to lay off third of workforce in bid to slash operating costs</a>",
    "summary": "```json\n{\n  \"summary\": \"Geron Corporation is laying off one-third of its workforce as part of a cost-cutting initiative. This restructuring follows the company's recent regulatory approval received la",
    "url": "https://www.fiercepharma.com/pharma/geron-lay-13-workforce-quest-slash-operating-costs-maximize-rytelo-launch",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ose-narrows-focus-conserve-cash-expense-wider-pipeline\" hreflang=\"en\">Ose narrows focus to conserve cash at expense of wider pipeline</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/ose-narrows-focus-conserve-cash-expense-wider-pipeline",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/amgen-obesity-marketing-leader-chris-boulton-takes-reins-metabolic-biotech-prolynx\" hreflang=\"en\">Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx</a>",
    "summary": "```json\n{\n  \"summary\": \"Chris Boulton, a veteran with three decades of experience in sales and marketing at major pharmaceutical companies, is leaving his position as obesity marketing leader at Amgen",
    "url": "https://www.fiercepharma.com/marketing/amgen-obesity-marketing-leader-chris-boulton-takes-reins-metabolic-biotech-prolynx",
    "date": "2025-12-11",
    "companies_detected": [
      "Amgen",
      "Prolynx"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/pfizers-cost-cutting-drive-reaches-switzerland-where-company-plans-lay-hundreds-year-end\" hreflang=\"en\">Pfizer's cost-cutting drive reaches Switzerland, where company plans to lay off hundreds by year-end: Bloomberg</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer is implementing layoffs in Switzerland as part of a multi-year cost-cutting initiative, with hundreds of employees expected to be laid off by year-end. The company state",
    "url": "https://www.fiercepharma.com/pharma/pfizers-cost-cutting-drive-reaches-switzerland-where-company-plans-lay-hundreds-year-end",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease\" hreflang=\"en\">ASH: Novartis details ianalumab's phase 3 win in rare blood disease</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/ash-novartis-details-ianalumabs-phase-3-win-rare-blood-disease",
    "date": "2025-12-11",
    "companies_detected": [
      "Novartis"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/abbott-extends-rally-serena-williams-lingo-cgm-push\" hreflang=\"en\">Abbott teams up with Serena Williams again in Lingo CGM push</a>",
    "summary": "```json\n{\n  \"summary\": \"Abbott has partnered again with tennis star Serena Williams to promote its Lingo over-the-counter continuous glucose monitoring (CGM) sensor. This represents a continued celebr",
    "url": "https://www.fiercepharma.com/marketing/abbott-extends-rally-serena-williams-lingo-cgm-push",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/fda-awards-1st-national-priority-nod-usantibiotics-augmentin-xr-after-2-month-review\" hreflang=\"en\">FDA awards 1st national priority nod to USAntibiotics' Augmentin XR</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved the first drug under its new Commissioner's National Priority Voucher pilot review program. USAntibiotics received approval for Augmentin XR, a domesticall",
    "url": "https://www.fiercepharma.com/manufacturing/fda-awards-1st-national-priority-nod-usantibiotics-augmentin-xr-after-2-month-review",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/uk-cuts-medicine-discount-rate-us-intervention\" hreflang=\"en\">In win for pharma, UK cuts medicine rebate rate following US intervention</a>",
    "summary": "```json\n{\n  \"summary\": \"The UK has reduced the rebate rate that pharmaceutical companies must pay under its medicine cost-control scheme, following a recent trade deal with the US. This policy change ",
    "url": "https://www.fiercepharma.com/pharma/uk-cuts-medicine-discount-rate-us-intervention",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ftc-claims-win-teva-moves-delist-hundreds-patents-fda-orange-book\" hreflang=\"en\">FTC claims a win as Teva moves to delist hundreds of patents from FDA Orange Book, agency says</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/ftc-claims-win-teva-moves-delist-hundreds-patents-fda-orange-book",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/italian-non-profit-fondazione-telethon-lands-fda-approval-first-gene-therapy-treat-rare\" hreflang=\"en\">Italian nonprofit lands FDA approval for first gene therapy to treat rare genetic disease</a>",
    "summary": "```json\n{\n  \"summary\": \"Italian nonprofit Fondazione Telethon received FDA approval for Waskyra, the first gene therapy to treat Wiskott-Aldrich syndrome. Waskyra is an ex vivo gene therapy that addre",
    "url": "https://www.fiercepharma.com/pharma/italian-non-profit-fondazione-telethon-lands-fda-approval-first-gene-therapy-treat-rare",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/fda-finalizes-guidance-promotional-materials-biologics-and-biosimilars\" hreflang=\"en\">FDA finalizes guidance on promotional materials for biologics and biosimilars</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA has finalized guidance on promotional materials for prescription biologics and biosimilars. The document provides recommendations to manufacturers on how to approach ad",
    "url": "https://www.fiercepharma.com/marketing/fda-finalizes-guidance-promotional-materials-biologics-and-biosimilars",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/az-gilead-backed-program-reduced-side-effects-distress-black-breast-cancer-patients-study\" hreflang=\"en\">AZ-, Gilead-backed program reduced side effects, distress in Black breast cancer patients: study</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/marketing/az-gilead-backed-program-reduced-side-effects-distress-black-breast-cancer-patients-study",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/cdmo-adare-plots-137-layoffs-philly-shortly-after-transplanting-headquarters-new\" hreflang=\"en\">CDMO Adare plots 137 layoffs in Philly shortly after transplanting headquarters from N.J.</a>",
    "summary": "```json\n{\n  \"summary\": \"CDMO Adare Pharma Solutions is planning to lay off 137 employees at a Philadelphia facility. This comes approximately 18 months after the company announced plans to relocate it",
    "url": "https://www.fiercepharma.com/manufacturing/cdmo-adare-plots-137-layoffs-philly-shortly-after-transplanting-headquarters-new",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/cdmos-bora-corealis-link-provide-one-stop-shop-oral-solid-dose-production-development\" hreflang=\"en\">CDMOs Bora, Corealis link up to provide one-stop shop for oral solid dose production, development</a>",
    "summary": "```json\n{\n  \"summary\": \"CDMOs Bora and Corealis have formed a strategic alliance to create an end-to-end service offering for oral solid dose drug development and production. The partnership aims to s",
    "url": "https://www.fiercepharma.com/manufacturing/cdmos-bora-corealis-link-provide-one-stop-shop-oral-solid-dose-production-development",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/after-deal-spree-supreme-group-unites-agencies-form-pr-and-communications-group\" hreflang=\"en\">After deal spree, Supreme Group unites agencies to form new PR and communications group</a>",
    "summary": "```json\n{\n  \"summary\": \"Supreme Group has consolidated two of its acquired companies, Amendola Communications and Health+Commerce, to form a new PR and communications agency. This consolidation follow",
    "url": "https://www.fiercepharma.com/marketing/after-deal-spree-supreme-group-unites-agencies-form-pr-and-communications-group",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/pfizer-tukysa-delays-her2-breast-cancer-progression-first-line-maintenance-therapy\" hreflang=\"en\">Pfizer's Tukysa delays HER2 breast cancer progression as 1st-line maintenance therapy</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer has released detailed trial data showing that Tukysa can delay disease progression in HER2-positive breast cancer when used as first-line maintenance therapy. The result",
    "url": "https://www.fiercepharma.com/pharma/pfizer-tukysa-delays-her2-breast-cancer-progression-first-line-maintenance-therapy",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/viatris-returns-stake-biocon-biologics-815m-setting-biosimilar-market-re-entry-biocon\" hreflang=\"en\">Biocon buys out Viatris and others from biosimilar subsidiary</a>",
    "summary": "```json\n{\n  \"summary\": \"Biocon is buying back Viatris' stake in its biosimilar subsidiary Biocon Biologics for $815 million. This transaction allows Viatris to re-enter the biosimilar market, which it",
    "url": "https://www.fiercepharma.com/pharma/viatris-returns-stake-biocon-biologics-815m-setting-biosimilar-market-re-entry-biocon",
    "date": "2025-12-11",
    "companies_detected": [
      "Biocon"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/genentech-uncovers-hidden-gems-latest-iteration-multiple-sclerosis-visibility-drive\" hreflang=\"en\">Genentech uncovers 'Hidden GeMS' in latest iteration of multiple sclerosis visibility drive</a>",
    "summary": "```json\n{\n  \"summary\": \"Genentech has launched a new edition of its 'Hidden GeMS' awareness campaign focused on multiple sclerosis. The campaign highlights the talents and passions of people living wi",
    "url": "https://www.fiercepharma.com/marketing/genentech-uncovers-hidden-gems-latest-iteration-multiple-sclerosis-visibility-drive",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/eye-ai-imre-hires-nadine-lafond-ogilvy-fill-ceo-vacancy\" hreflang=\"en\">With eye on AI, Imre hires Nadine Lafond from Ogilvy Health to fill CEO vacancy</a>",
    "summary": "```json\n{\n  \"summary\": \"Imre, an advertising agency, has appointed Nadine Lafond from Ogilvy Health as its new CEO. The hire is part of the company's strategic focus on artificial intelligence capabil",
    "url": "https://www.fiercepharma.com/marketing/eye-ai-imre-hires-nadine-lafond-ogilvy-fill-ceo-vacancy",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/roll-tide-lilly-selects-alabama-site-location-6b-api-facility-0\" hreflang=\"en\">Roll Tide: Lilly selects Alabama site as location for $6B API facility</a>",
    "summary": "```json\n{\n  \"summary\": \"Eli Lilly has selected Huntsville, Alabama as the location for a $6 billion manufacturing facility. This plant will be the third of four large-scale U.S. manufacturing faciliti",
    "url": "https://www.fiercepharma.com/pharma/roll-tide-lilly-selects-alabama-site-location-6b-api-facility-0",
    "date": "2025-12-11",
    "companies_detected": [
      "Eli Lilly"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/biosecure-legislation-makes-way-key-us-defense-bill-teeing-potential-china-biopharma\" hreflang=\"en\">Biosecure Act slips into key US defense bill, teeing up potential China biopharma constraints in '26</a>",
    "summary": "```json\n{\n  \"summary\": \"The Biosecure Act has been incorporated into the National Defense Authorization Act for fiscal year 2026. This legislation would restrict certain Chinese life sciences companie",
    "url": "https://www.fiercepharma.com/pharma/biosecure-legislation-makes-way-key-us-defense-bill-teeing-potential-china-biopharma",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/once-public-now-private-gamida-cell-scores-2nd-fda-nod-stem-cell-therapy-omisirge\" hreflang=\"en\">Once public, now private, Gamida Cell scores 2nd FDA nod for stem cell therapy Omisirge</a>",
    "summary": "```json\n{\n  \"summary\": \"Gamida Cell, now a private company after previously being public, has received FDA approval to expand the use of its cell therapy Omisirge for treating severe aplastic anemia. ",
    "url": "https://www.fiercepharma.com/pharma/once-public-now-private-gamida-cell-scores-2nd-fda-nod-stem-cell-therapy-omisirge",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-now-has-merck-az-and-sanofi-rsv-shots-infants-its-crosshairs-reuters\" hreflang=\"en\">FDA now has Merck, AZ and Sanofi RSV shots for infants in its crosshairs: Reuters</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/fda-now-has-merck-az-and-sanofi-rsv-shots-infants-its-crosshairs-reuters",
    "date": "2025-12-11",
    "companies_detected": [
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma\" hreflang=\"en\">ASH: J&amp;J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma</a>",
    "summary": "```json\n{\n  \"summary\": \"Johnson & Johnson presented positive trial data at ASH for a combination therapy involving Tecvayli, a bispecific antibody for multiple myeloma. The data suggests this combinat",
    "url": "https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/pfizer-lilly-jj-and-more-see-inclusions-chinas-first-batch-picks-new-private-insurance\" hreflang=\"en\">Meds from Pfizer, Lilly, J&amp;J and more secure spots in China's 1st private insurance formulary</a>",
    "summary": "```json\n{\n  \"summary\": \"China's National Healthcare Security Administration announced its first batch of 19 medications selected for the new Commercial Health Insurance Innovative Drug Catalogue. The ",
    "url": "https://www.fiercepharma.com/pharma/pfizer-lilly-jj-and-more-see-inclusions-chinas-first-batch-picks-new-private-insurance",
    "date": "2025-12-11",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/its-future-still-limbo-csl-seqirus-debuts-1b-flu-shot-antivenom-plant-australia\" hreflang=\"en\">Its future still in limbo, CSL Seqirus debuts $1B flu shot, antivenom plant in Australia</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/manufacturing/its-future-still-limbo-csl-seqirus-debuts-1b-flu-shot-antivenom-plant-australia",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)",
    "summary": "```json\n{\n  \"summary\": \"MedinCell has published its consolidated half-year financial results for the period from April 1st, 2025 to September 30, 2025. This announcement provides stakeholders with an ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults",
    "summary": "```json\n{\n  \"summary\": \"Teva Pharmaceuticals, in partnership with MedinCell, has submitted a New Drug Application (NDA) to the U.S. FDA for TEV-'749/mdc-TJK, an olanzapine extended-release injectable ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [
      "olanzapine"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "summary": "```json\n{\n  \"summary\": \"MedinCell has been awarded a new grant to support its efforts in fighting malaria. This funding will likely advance the company's research and development programs focused on m",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "[Replay] Jefferies Global Healthcare Conference 2025",
    "summary": "```json\n{\n  \"summary\": \"This is a replay announcement for the Jefferies Global Healthcare Conference 2025. The text provides minimal information beyond the conference name and indicates it is a replay",
    "url": "https://wsw.com/webcast/jeff332/medcl/1970687",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/lilly-oncology-chief-sees-jaypirca-sweet-spot-second-line-cll-despite-first-line-btk-trial\" hreflang=\"en\">ASH: Lilly oncology chief sees sweet spot for Jaypirca in 2nd-line CLL despite 1st-line trial wins</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/lilly-oncology-chief-sees-jaypirca-sweet-spot-second-line-cll-despite-first-line-btk-trial",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference",
    "summary": "```json\n{\n  \"summary\": \"MedinCell's management will present at two upcoming healthcare conferences: the 8th Annual Evercore Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conferenc",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Evercore-Piper_Sandler_EN_27112025.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "summary": "```json\n{\n  \"summary\": \"MedinCell has appointed Dr. Grace Kim as Chief Strategy Officer for U.S. Finance to support the company's next phase of capital growth in the United States. This corporate appo",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)",
    "summary": "```json\n{\n  \"summary\": \"MedinCell announced its participation in two upcoming healthcare investor conferences: the UBS Global Healthcare Conference in Palm Beach and the Stifel Healthcare Conference i",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_UBS-STIFEL_06112025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Videoconference and publication of half-year financial results, Tuesday, December 9, 2025",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_ConfHYR_01122025_EN.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "summary": "```json\n{\n  \"summary\": \"Teva's UZEDY® (risperidone extended-release injectable suspension) continues to demonstrate strong commercial growth. The company is preparing to submit a New Drug Application ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [
      "olanzapine"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder",
    "summary": "```json\n{\n  \"summary\": \"The FDA has approved an expanded indication for UZEDY (risperidone extended-release injectable suspension) for the treatment of adults with Bipolar I Disorder. This represents ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_UZEDY-BDI_EN_10102025_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [],
    "molecules_detected": [
      "risperidone"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)",
    "summary": "```json\n{\n  \"summary\": \"MedinCell announced its participation in the 2025 Truist Securities Biopharma Symposium taking place in New York. This is a corporate event where the company will likely presen",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_Truist_22102025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "summary": "```json\n{\n  \"summary\": \"MedinCell announced it will be added to the MSCI World Small Cap Index, a prominent global equity benchmark. This inclusion represents a significant corporate milestone for the",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "date": "2025-12-11",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  }
]